Related Experiment Video
Updated: Oct 2, 2026

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube (SWCNT)-delivered MALAT1 Antisense Oligos
Published on: December 13, 2018
Treatment of Multiple Myeloma: ASCO Living Guideline, Version 2026.1.3
Rahul Banerjee1, Hans Messersmith2, Mohammad Ebraheem3
1Fred Hutchinson Cancer Center, Seattle, WA, USA.
Abstract:
[Box: see text]Living guidelines are developed for selected topic areas with rapidly evolving evidence that drives frequent change in recommended clinical practice. Living guidelines are updated on a regular schedule by a standing expert panel that systematically reviews the health literature on a continuous basis, as described in the ASCO Guidelines Methodology Manual. ASCO Living Guidelines follow the ASCO Conflict of Interest Policy Implementation for Clinical Practice Guidelines. Living Guidelines and updates are not intended to substitute for independent professional judgment of the treating clinician and do not account for individual variation among patients. See appendix for disclaimers and other important information (Appendix I and Appendix II). Updates are published regularly and can be found on the ASCO Publications website.
Related Concept Videos
Standards of Care II
Tumor Immunotherapy